Abstract
OBJECTIVE AND DESIGN: It has been proposed that the anti-obesity agent, phentermine, may act in part via inhibition of monoamine oxidase (MAO). The ability of phentermine to inhibit both MAOA and MAOB in vitro has been examined along with that of the fenfluramine isomers, a range of selective serotonin reuptake inhibitors and sibutramine and its active metabolites.
RESULTS: In rat brain, harmaline and lazabemide showed potent and selective inhibition of MAOA and MAOB, their respective target enzymes, with IC50 values of 2.3 and 18 nM. In contrast, all other drugs examined were only weak inhibitors of MAOA and MAOB with IC50 values for each enzyme in the moderate to high micromolar range. For MAOA, the IC50 for phentermine was estimated to be 143 µM, that for S(+)-fenfluramine, 265 µM and that for sertraline, 31 µM. For MAOB, example IC50s were as follows: phentermine (285 µM), S(+)-fenfluramine (800 µM) and paroxetine (16 µM). Sibutramine was unable to inhibit either enzyme, even at its limit of solubility.
CONCLUSION: We therefore suggest that MAO inhibition is unlikely to play a role in the pharmacodynamic properties of any of the tested drugs, including phentermine. Instead, the lack of potency of these drugs as MAO inhibitors is contrasted with their powerful ability either to inhibit the uptake of one or more monoamines (fluoxetine, paroxetine, sertraline, sibutramine's active metabolites) or to evoke the release of one or more monoamines (S(+)-fenfluramine, S(+)-norfenfluramine, phentermine). These differences in mode of action may be linked to the adverse cardiovascular events experienced with some of the releasing agents.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Connolly HM, McGoon MD . Obesity drugs and the heart Curr Probl Cardiol 1999 24: 751–792.
Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C, Reid CL . Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine JAMA 2000 283: 1703–1709.
Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simmoneau G, Bégaud B . Appetite-suppressant drugs and the risk of primary pulmonary hypertension New Engl J Med 1996 335: 609–616.
Fishman AP . Aminorex to Fen/Phen. An epidemic foretold Circulation 1999 99: 156–161.
Hervé P, Launay J-M, Scrobohaci M-L, Brenot F, Simonneau G, Petitpretz P, Poubeau P, Cerrina J, Duroux P, Drouet L . Increased plasma serotonin in primary pulmonary hypertension Am J Med 1995 99: 249–254.
Robiolio PA, Rigolin VH, Wilson JS, Harrison JK, Sanders LL, Bashore TM, Feldman JM . Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography Circulation 1995 92: 790–795.
Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun J-H, Link JR, Abbaszade I, Hollis JM, Largent BL, Hartig PR, Hollis GF, Meunier PC, Robichaud AJ, Robertson DW . Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine Mol Pharmac 2000 57: 75–81.
Baumann MH, Ayestas MA, Dersch CM, Brockington A, Rice KC, Rothman RB . Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: therapeutic implications Synapse 2000 36: 102–113.
Rowley HL, Butler SA, Prow MR, Dykes SG, Aspley S, Kilpatrick IC, Heal DJ . A comparison of the effects of sibutramine and other weight-modifying drugs on extracellular dopamine in the nucleus accumbens of freely-moving rats Synapse 2000 38: 167–176.
Ulus IH, Maher TJ and Wurtman RJ . Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors Biochem Pharmac 2000 59: 1611–1621.
Rothman RB . Is phentermine an inhibitor of monoamine oxidase? A critical appraisal. Synapse 1999 32: 141–145.
Kilpatrick IC, Traut M, Heal DJ . Monoamine oxidase inhibition determined in rat brain is unlikely to account for cardiovascular risks associated with fenfluramine and phentermine Br J Pharmac 1999 128: 66P.
Wurtman RJ, Axelrod J . A sensitive and specific assay for the estimation of monoamine oxidase Biochem Pharmac 1963 12: 1439–1441.
Fuentes JA, Neff NH . Selective monoamine oxidase inhibitor drugs as aids in evaluating the role of type A and B enzymes Neuropharmacology 1975 14: 819–825.
Henriot S, Kuhn C, Kettler R, Da Prada M . Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: preclinical and clinical findings J Neural Transm 1994 41 (Suppl): 321–325.
Leonardi ETK, Azmitia EC . MDMA (Ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac) Neuropsychopharmacology 1994 10: 231–238.
Holt A, Baker GB . Inhibition of rat brain monoamine oxidase enzymes by fluoxetine and norfluoxetine Naunyn-Schmiedeberg's Arch Pharmac 1996 354: 17–24.
Mukherjee J, Yang Z-Y . Evaluation of monoamine oxidase B inhibition by fluoxetine (Prozac): an in vitro and in vivo study Eur J Pharmac 1997 337: 111–114.
Buckett WR, Thomas PC, Luscombe GP . The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down-regulation Prog Neuro-Psychopharmac Biol Psychiatr 1988 12: 575–584.
Moller Nielsen I, Dubnick B . Pharmacology of chlorphentermine. In: Costa E, Garattini S (eds). Amphetamines and related compounds. Raven Press: New York 1970 63–73.
Seiler K-U, Wasserman O . MAO-inhibitory properties of anorectic drugs J Pharm Pharmac 1973 25: 576–578.
Haefely W, Burkard WP, Cesura AM, Kettler R, Lorez HP, Martin JR, Richards JG, Scherschlicht R, Da Prada M . Biochemistry and pharmacology of moclobemide, a prototype RIMA Psychopharmacology 1992 106: (Suppl): S6–14.
Duhault J, Verdavainne C . Modification du taux de sérotonine cérébrale chez le rat par les triflurométhyl-phényl-2 éthyl aminopropane (fenfluramine 768 S) Arch Int Pharmacodyn 1967 170: 276–286.
Morgan D, Löfstrandh S, Costa E . Amphetamine analogues and brain amines Life Sci 1972 11: 83–96.
Buczko W, De Gaetano G, Garattini S . Effect of fenfluramine on 5-hydroxytryptamine uptake and release by rat blood platelets Br J Pharmac 1975 53: 563–568.
Lane, EL, Prow, MR, Aspley, S, Kilpatrick IC, Heal DJ . d-Fenfluramine releases 5HT from whole blood of rats as measured by in vitro microdialysis Br J Pharmac 2000 129: 155P.
Celada P, Martin F, Artigas F . Effects of chronic treatment with dexfenfluramine on serotonin in rat blood, brain and lung tissue Life Sci 1994 55: 1237–1243.
Redmon B, Raatz S, Bantle JP . Valvular heart disease associated with fenfluramine-phentermine New Engl J Med 1997 337: 1773–1774.
Rothman RB, Redmon JB, Raatz SK, Kwong CA, Swanson JE, Bantle JP . Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin Am J Cardiol 2000 85: 913–915.
Heal DJ, Cheetham SC, Prow MR, Martin KF, Buckett WR . A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents Br J Pharmacol 1998 125: 301–308.
Cheetham SC, Viggers JA, Slater NA, Heal DJ, Buckett WR . [3H]Paroxetine binding in rat frontal cortex strongly correlates with [3H]5-HT uptake: effect of administration of various antidepressant treatments Neuropharmacology 1993 32: 737–743.
Rothman RB, Ayestas MA, Dersch CM, Baumann MH . Aminorex, fenfluramine and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension Circulation 1999 100: 869–875.
Lancashire B, Viggers J, Prow MR, Aspley S, Martin KF, Cheetham SC, Heal DJ . Monamine release and uptake inhibition profiles of antiobesity agents J Psychopharmacol 1998 12 (Suppl A): 143P.
Acknowledgements
We are grateful for the skilful assistance of Willi Hoffman and Ingrid Volk.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is dedicated to the late Professor Michael J Stock, colleague and friend.
Rights and permissions
About this article
Cite this article
Kilpatrick, I., Traut, M. & Heal, D. Monoamine oxidase inhibition is unlikely to be relevant to the risks associated with phentermine and fenfluramine: a comparison with their abilities to evoke monoamine release. Int J Obes 25, 1454–1458 (2001). https://doi.org/10.1038/sj.ijo.0801732
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijo.0801732
Keywords
This article is cited by
-
Garcinia kola: a critical review on chemistry and pharmacology of an important West African medicinal plant
Phytochemistry Reviews (2023)
-
Pharmacology of stimulants prohibited by the World Anti‐Doping Agency (WADA)
British Journal of Pharmacology (2008)
-
Platelet monoamine oxidase B (MAO-B) activity and its relationship to DL-fenfluramine-induced prolactin response in healthy men
Journal of Neural Transmission (2006)
-
Additive effects on rat brain 5HT release of combining phentermine with dexfenfluramine
International Journal of Obesity (2001)